Ivenix Appoints New Head With $42m Cash Infusion
This article was originally published in Clinica
Ivenix, a company developing a next-generation infusion pump system, has appointed Stuart Randle CEO. The appointment comes a few months after the Amesbury, Massachusetts firm bagged a $42m financing round, led by new investor, China-based WuXi Healthcare Ventures. Prior to joining Ivenix, Randle was president and CEO of another Massachusetts firm, GI Dynamics, which was focused on type 2 diabetes and obesity. The infusion system market is not new to Ivenix’s new head: he began his career at Baxter where he spent 10 years in various senior sales and marketing roles.